Oshnouei S, Salarilak Sh, Khalkhali A, Karamyar M, Rahimi Rad Mh, Delpishe A
MSc student of Epidemiology, Epidemiology and Biostatistics Department, Faculty of Medicine, Urmia Medical University, Iran.
Iran Red Crescent Med J. 2012 Oct;14(10):641-6. Epub 2012 Oct 30.
Acetaminophen exposure might be associated with increasing risk of asthma prevalence and other atopic disorders over recent decades. The present study aimed to investigate the association between acetaminophen exposure and the risk of developing childhood asthma.
A case - control study was undertaken between March and September 2010 in Urmia district north west of Iran. Subjects were children aged between 2 - 8 years old. Cases were asthmatic children diagnosed based on GINA criteria (n=207) and controls were children without asthma symptoms (n=414) using 1:2 sampling method. Cases and controls were matched for age and gender. Clinical data including Acetaminophen exposure was collected by a questionnaire which completed by interviewing with parents/ guardians.
Using Acetaminophen during the first year of life had no any effect on the risk of asthma (p=0.19), but amongst 2-8 years old children, this association was observed (p<0.001). There was also a doseresponseassociation between Acetaminophen consumption and risk of asthma (OR: 3.8; 95% CI; 2.15 6.59 for once per 2 to 3 month and OR: 4.2; 2.50 - 7.3 for at least one per month).
Using Acetaminophen increases risk of asthma among 2 - 8 years old children. However stronger evidences are required to design evidence-based guidelines to reduce acetaminophen consumption following post - vaccination and other febrile disorders.
近几十年来,对乙酰氨基酚的接触可能与哮喘患病率及其他特应性疾病风险增加有关。本研究旨在调查对乙酰氨基酚接触与儿童哮喘发病风险之间的关联。
2010年3月至9月在伊朗西北部的乌尔米耶地区进行了一项病例对照研究。研究对象为2至8岁的儿童。病例为根据全球哮喘防治创议(GINA)标准确诊的哮喘儿童(n = 207),对照组为无哮喘症状的儿童(n = 414),采用1:2抽样方法。病例和对照按年龄和性别进行匹配。包括对乙酰氨基酚接触情况在内的临床数据通过对父母/监护人进行访谈后填写的问卷收集。
出生后第一年使用对乙酰氨基酚对哮喘风险无任何影响(p = 0.19),但在2至8岁儿童中,观察到了这种关联(p < 0.001)。对乙酰氨基酚的服用量与哮喘风险之间也存在剂量反应关系(每2至3个月服用一次,比值比[OR]:3.8;95%置信区间[CI]:2.15至6.59;每月至少服用一次,OR:4.2;2.50至7.3)。
在2至8岁儿童中,使用对乙酰氨基酚会增加哮喘风险。然而,需要更有力的证据来制定基于证据的指南,以减少接种疫苗后及其他发热性疾病后对乙酰氨基酚的服用量。